Smith, C H <br/><br/>
Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.  [electronic resource] 

 -  The British journal of dermatology  Jul 2006 
 - 160-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0007-0963 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2133.2006.07316.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abscess--etiology<br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Autoantibodies--blood<br/>Carcinoma, Basal Cell--etiology<br/>Carcinoma, Renal Cell--etiology<br/>Cellulitis--etiology<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hypertension--etiology<br/>Immunosuppressive Agents--adverse effects<br/>Infliximab<br/>Kidney Neoplasms--etiology<br/>Lentigo--etiology<br/>Liver Diseases--etiology<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Psoriasis--drug therapy<br/>Respiratory Tract Infections--etiology<br/>Skin Neoplasms--etiology<br/>Thrombocytopenia--etiology<br/>Time Factors<br/>Treatment Outcome<br/>Tuberculosis--etiology<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors